Clinical Research Grows in England
The new Research Activity League Table from the NIHR Clinical Research Network shows all NHS trusts or hospital groups in England are delivering clinical research and over 60% increased their research activity last year.
The new Research Activity League Table from the National Institute for Health Research (NIHR) Clinical Research Network (CRN) shows all National Health Service (NHS) trusts or hospital groups in England are delivering clinical research and over 60% increased their research activity last year.
Commercial research activity is an added feature for the 2015/16 league table, which found that 36% of studies were new commercial contract studies last year.
“This year’s league table results highlight for the first time the growing importance of commercial research for the NHS in England,” said Dr. Jonathan Sheffield, Chief Executive Officer of the NIHR CRN. “Commercial involvement in clinical research speeds up the development and availability of new treatments, therapies and diagnostics for NHS patients. The U.K. is a destination of choice with 35,000 participants recruited to studies sponsored by the life sciences industry in England last year.”
Barts Health NHS Trust in London came top of the league table for the amount of commercial studies delivered (114 studies), and also had the biggest increase in studies from last year (279 to 335), along with Imperial College Healthcare NHS Trust (365 to 421).
The following NHS trust types were ranked top in terms of the largest quantity of research for 2015/16:
- Acute: The Newcastle Upon Tyne Hospitals NHS Foundation Trust (537 studies)
- Mental health: South London and Maudsley NHS Foundation Trust (94 studies)
- Clinical commissioning groups: NHS Oxfordshire (51 studies)
- Care: Lancashire Care NHS Foundation Trust (50 studies)
- Ambulance: South Western Ambulance Service NHS Foundation Trust (8 studies)
The top five trusts achieving the biggest step-change in research activity (study increase) were as follows:
- Barts Health NHS Trust [56 study increase] and Imperial College Healthcare NHS Trust [56 study increase]
- Oxford University Hospitals NHS Foundation Trust [52 study increase]
- Royal Free London NHS Foundation Trust [51 study increase]
- Sheffield Teaching Hospitals NHS Foundation Trust [44 study increase]
- Chelsea and Westminster Hospital NHS Foundation Trust [41 study increase]
The National Institute for Health Research (NIHR) is funded by the Department of Health, and is the research arm of the NHS. It was established in April 2006. To view the full league table, go to www.nihr.ac.uk/nihrleaguetable.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.
